Researchers found that patients with both bronchiectasis and chronic rhinosinusitis are more likely to test positive for Pseudomonas aeruginosa (P aeruginosa).
Researchers found that patients with both bronchiectasis and chronic rhinosinusitis are more likely to test positive for Pseudomonas aeruginosa (P aeruginosa).
Read More
Veterans with chronic rhinosinusitis (CRS) who were exposed to burn pits and other toxins show a marked increase in sinus mast cells.
Read More
Sleep quality for patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) improved after endoscopic surgery, showing longer REM sleep durations, according to a study published in Sleep Science.
Read More
Airiver received investigational device exemption approval from the US FDA to begin a pivotal clinical trial of the Airiver ESSpand Sinus Drug Coated Balloon in patients with chronic rhinosinusitis.
Read More
American military veterans deployed to Iraq or Afghanistan had a higher risk of asthma, chronic rhinitis, chronic rhinosinusitis, and nasal polyposis compared with non-deployed peers.
Read More
The European Commission approved Tezspire (tezepelumab) as an add-on therapy with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
Tezspire (tezepelumab-ekko) is now FDA-approved for chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 and older.
Read More
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
ERS leaders are calling for health systems to prioritize and integrate the care of chronic respiratory diseases (CRDs) across Europe.
Read More
Sinus and congestion problems are more than just earthly annoyances, according to new research on astronauts from the International Space Station.
Read More
Omlyclo (omalizumab-igec) is the first and only biosimilar designated as interchangeable with Xolair (omalizumab) for the treatment of moderate to severe persistent asthma, CRSwNP, IgE-mediated food allergy, and chronic spontaneous urticaria.
Read More
Patients using mepolizumab (Nucala) experienced significant improvement in nasal polyps, nasal obstruction, smell and overall symptoms.
Read More
Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Read More
